age-of-ai
age-of-ai-canada-event-2026

Dr. Muhammad Mamdani, PharmD, MA, MPH

Clinical Lead, AI
Ontario Health

Dr. Muhammad Mamdani, PharmD, MA, MPH

Clinical Lead, AI
Ontario Health
Age of AI Canada, 2024
Age of AI Canada, 2026

Muhammad Mamdani, PharmD, MA, MPH Clinical Lead, AI - Ontario Health Faculty Affiliate – Vector Institute Professor – University of Toronto Director – University of Toronto Temerty Centre for Artificial Intelligence Research and Education Medicine (T-CAIREM) Affiliate Scientist – IC/ES Professor, University of Toronto Dr. Mamdani is Vice President of Data Science and Advanced Analytics at Unity Health Toronto and Director of the University of Toronto Temerty Faculty of Medicine Centre for Artificial Intelligence Research and Education in Medicine (T-CAIREM). Dr. Mamdani’s team bridges advanced analytics including machine learning with clinical and management decision making to improve patient outcomes and hospital efficiency with over 50 AI solutions developed and deployed into clinical practice. Dr. Mamdani is also Professor in the Department of Medicine of the Temerty Faculty of Medicine, the Leslie Dan Faculty of Pharmacy, and the Institute of Health Policy, Management and Evaluation of the Dalla Lana School of Public Health. He is also Affiliate Scientist at IC/ES and a Faculty Affiliate of the Vector Institute, which is a leading institution for artificial intelligence research in Canada. Further, Dr. Mamdani is a member of the Human Drug Advisory Panel of the Patented Medicine Prices Review Board (PMPRB). Previously, Dr. Mamdani founded the Ontario Drug Policy Research Network (ODPRN), which is among the world’s most impactful collaborations between researchers and drug policy decision-makers. He was also the Founding Director of the Li Ka Shing Centre for Healthcare Analytics Research and Training (LKS-CHART) of Unity Health Toronto and the Founding Director of the Applied Health Research Centre (AHRC) of the Li Ka Shing Knowledge Institute of Unity Health Toronto, which is Toronto’s leading academic research organization focused on the design and implementation of multicentre clinical research initiatives including large randomized clinical trials. In 2010, Dr. Mamdani was named among Canada’s Top 40 under 40. Prior to joining the Li Ka Shing Knowledge Institute and Unity Health Toronto, Dr. Mamdani was a Director of Outcomes Research at Pfizer Global Pharmaceuticals in New York. Dr. Mamdani’s research interests include pharmacoepidemiology, pharmacoeconomics, drug policy, and the application of advanced analytics approaches to clinical problems and health policy decision-making. He has published over 500 research studies in peer-reviewed medical journals, including leading journals such as the New England Journal of Medicine, the Lancet, the Journal of the American Medical Association, the British Medical Journal, and Annals of Internal Medicine. His research has been cited over 45,000 times and has an h-index of over 100. Dr. Mamdani obtained a Doctor of Pharmacy degree (PharmD) from the University of Michigan (Ann Arbor) in 1995 and subsequently completed a fellowship in pharmacoeconomics and outcomes research at the Detroit Medical Center in 1997. During his fellowship, Dr. Mamdani obtained a Master of Arts degree in Economics from Wayne State University in Detroit, Michigan with a concentration in econometric theory. He then completed a Master of Public Health degree from Harvard University in 1998 with a concentration in quantitative methods, focusing on biostatistics and epidemiological principles.

Speaker's program:

16:10

-

16:40

Closing Discussion - AI and the workforce, where is it all going?

Denisse Irrgang
,
AI Sr. Product Manager
,
AstraZeneca
Paul Costea
,
Systems Process Analyst
,
Roche
Dr. Muhammad Mamdani, PharmD, MA, MPH
,
Clinical Lead, AI
,
Ontario Health
David Brown
,
Executive Vice President of Health Strategy
,
NFA Health

15:30

-

15:50

How Life Sciences Should Support a More Connected, AI Powered, Patient-Centred Future

  • As AI helps health systems identify patients earlier, reveal gaps in care, and support faster clinical decisions, life science companies have an opportunity to play a more meaningful role in improving system outcomes.
  • Hear from Ontario’s Clinical AI Lead on what this shift looks like in practice, and what it means for patient support, HCP engagement, and future-facing medical and communications strategies. From patient finding and pathway visibility, to cross-sector collaboration, this session will show how life sciences can better align with the needs of a more connected healthcare system.

Dr. Muhammad Mamdani, PharmD, MA, MPH
,
Clinical Lead, AI
,
Ontario Health

15:05

-

15:30

Remain relevant: align with AI applications in hospitals

  • Understand the transformations underway in hospitals and broader health systems. From streamlined hospital workflows, to diminishing administrative overheads that help elevate patient care quality.
  • Discover the imperative for life science companies to evolve and integrate these tech-driven advancements to maintain relevance and foster meaningful connections with healthcare professionals.
  • Rare Disease use case: hear about an unmet need, that through collaboration and technology, could result in significant uplift in the diagnosis and treatment of multiple rare conditions.
Dr. Muhammad Mamdani, PharmD, MA, MPH
,
Clinical Lead, AI
,
Ontario Health

Join us November 26,  Toronto

REGISTER NOW

Join us at Age of AI, Europe. March 10.

Sold Out

Join us at SFE Canada. Oct 2, Toronto.

Register now

Join us at Age of AI, Europe. March 4.

THIS EVENT IS NOW SOLD OUT

Join us at Age of AI, Canada. June 17, Toronto.

REGISTER NOW